STOCK TITAN
  1. Home
  2. News
  3. ONCT

Oncternal Therapeutics, Inc. - ONCT STOCK NEWS

Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology therapies targeting cancers with significant unmet medical needs. The company's diverse product pipeline aims to address a wide range of malignancies, advancing novel therapeutic approaches with the potential to significantly improve patient outcomes.

One of Oncternal's flagship products is zilovertamab, a humanized monoclonal antibody that targets the receptor-tyrosine kinase-like orphan receptor 1 (ROR1). Currently in Phase 1/2 clinical trial, zilovertamab is being tested in combination with ibrutinib for mantle cell lymphoma and chronic lymphocytic leukemia, as well as in combination with paclitaxel for HER2-negative metastatic breast cancer.

Another key product in the pipeline is ONCT-216, a small molecule designed to inhibit ETS-family oncoproteins. ONCT-216 is undergoing Phase 1 trials to treat Ewing sarcoma, among other potential indications.

Oncternal is also developing ONCT-808, a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors. Furthermore, ONCT-534, a dual-action androgen receptor inhibitor, is in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms common in patients who have relapsed after standard treatments.

Financially, Oncternal remains robust, with ongoing clinical trials supported by solid operational funding. The company maintains strategic partnerships and collaborations to foster innovation and expedite the development of its therapeutic candidates. With a focus on unmet medical needs, Oncternal Therapeutics is at the forefront of oncology research, aiming to bring new hope to patients worldwide.

News

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Rhea-AI Summary
Oncternal Therapeutics, Inc. announced the dosing of the first patient in the fourth cohort of its Phase 1/2 study of ONCT-534 for the treatment of R/R Metastatic Castration-Resistant Prostate Cancer. The study involves the use of ONCT-534, a dual-action androgen receptor inhibitor, at a dose of 300 mg daily. The decision to escalate to this dose level was based on positive safety data and the potential for antitumor activity. The company's Chief Medical Officer expressed optimism about the program's progress and anticipates announcing efficacy and safety data by the end of the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
clinical trial
-
News

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

Rhea-AI Summary
Oncternal Therapeutics, Inc. (ONCT) to participate in a virtual fireside chat on new treatment options for prostate cancer. President and CEO to discuss the development of ONCT-534, a dual-acting androgen receptor inhibitor, and its potential in advanced prostate cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
News

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Oncternal Therapeutics, Inc. (ONCT) provides a business update and financial results for the fourth quarter of 2023. The company's Phase 1/2 study for ONCT-534, a dual-action androgen receptor inhibitor for advanced prostate cancer, is progressing well with encouraging initial response signals. ONCT-808, an autologous CAR T cell therapy for aggressive B-cell lymphoma, also shows promising results. The company has a cash runway projected into 2025, with $34.3 million in cash, cash equivalents, and short-term investments as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
earnings
News

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Oncternal Therapeutics, Inc. (ONCT) will report Q4 and full year 2023 financial results on March 7, 2024. A webcast will follow to discuss business updates and financial performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.85%
Tags
earnings
-
News

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced that its President and CEO, James Breitmeyer, M.D, Ph.D., will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The event will be held virtually, and the webcast link will be available on the company's website for at least 30 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
conferences
-
News

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Oncternal Therapeutics, Inc. announced the approval of an inducement award for a new employee, Damien Bresson, who will be joining as Senior Director, Preclinical and Translation Science. The award consists of an option to purchase 4,500 shares of Oncternal common stock, with a 10-year term and vesting over a four-year period. The award was approved by Oncternal’s compensation committee and will be granted as an inducement material to the employee entering into employment with Oncternal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
none
News

Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Rhea-AI Summary
Oncternal Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: ONCT), announced the enrollment of the fourth patient in its Phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor, for advanced prostate cancer. The study utilizes an adaptive Bayesian Optimal Interval (BOIN) design, with the last two patients enrolled in the third dosing cohort at 160 mg/day. The decision to proceed to dose level 3 was confirmed by the study’s Safety Review Committee (SRC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
clinical trial
-
News

Oncternal Therapeutics Announces Reverse Stock Split

Rhea-AI Summary
Oncternal Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: ONCT), has announced a 1-for-20 reverse stock split of its common stock effective January 8, 2024. The split aims to bring the company into compliance with Nasdaq's minimum bid price requirement, with no change in par value or authorized shares. All outstanding stock options, warrants, and equity incentive plans will be proportionately affected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26%
Tags
none
-
News

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announces approval of an inducement award for new employee Rebecca Nolan-Olson, consisting of an option to purchase 19,500 shares of Oncternal common stock under the 2021 Employment Inducement Incentive Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
News

Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) provides an update on its Phase 1/2 Study ONCT-808-101 for the ROR1-targeting autologous CAR T cell therapy ONCT-808 in patients with relapsed or refractory aggressive B-cell lymphoma. Initial results show promising complete and partial responses, with some adverse events. However, a fatal serious adverse event was reported in a patient at a higher dose level, prompting protocol changes and communication with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
clinical trial

FAQ

What is the current stock price of Oncternal Therapeutics (ONCT)?

The current stock price of Oncternal Therapeutics (ONCT) is $0.5266 as of December 4, 2024.

What is the market cap of Oncternal Therapeutics (ONCT)?

The market cap of Oncternal Therapeutics (ONCT) is approximately 1.6M.

What does Oncternal Therapeutics specialize in?

Oncternal Therapeutics specializes in developing novel oncology therapies targeting cancers with significant unmet medical needs.

What are the key products in Oncternal's pipeline?

Key products include zilovertamab, ONCT-216, ONCT-808, and ONCT-534, targeting various malignancies and currently in different phases of clinical trials.

What is zilovertamab?

Zilovertamab is a humanized monoclonal antibody targeting ROR1, in Phase 1/2 trials for mantle cell lymphoma, chronic lymphocytic leukemia, and HER2-negative metastatic breast cancer.

What is ONCT-534?

ONCT-534 is a dual-action androgen receptor inhibitor in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms in relapsed patients.

How is Oncternal funded?

Oncternal has solid operational funding supporting its ongoing clinical trials, with strategic partnerships and collaborations fostering innovation.

What makes ONCT-808 unique?

ONCT-808 is a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors.

What is the significance of ONCT-216?

ONCT-216 is a small molecule inhibitor of ETS-family oncoproteins, currently in Phase 1 trials to treat Ewing sarcoma and other potential indications.

What are the current clinical trials for Oncternal's products?

Ongoing trials include zilovertamab in Phase 1/2 for lymphoma and breast cancer, ONCT-534 in Phase 1/2 for prostate cancer, ONCT-808 in preclinical models, and ONCT-216 in Phase 1 for Ewing sarcoma.

Where can I find more information about Oncternal Therapeutics?

More information about Oncternal Therapeutics and its programs can be found on their official website at https://oncternal.com/.

How does Oncternal aim to address unmet medical needs?

Oncternal aims to address unmet medical needs by developing innovative therapies that target promising, yet untapped biological pathways implicated in cancer generation or progression.

Stock ONCT logo
Oncternal Therapeutics, Inc.

Nasdaq:ONCT

ONCT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ONCT Stock Data

1.56M
2.68M
9.23%
12.07%
0.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO